Status:
UNKNOWN
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
Lead Sponsor:
Vilnius University
Conditions:
Patients With Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.
Detailed Description
Cancer treatment with anthracyclines may cause heart damage and can lead to heart failure. There are drugs which may protect against cardiotoxic effects of anthracyclines (renin-angiotensin inhibitors...
Eligibility Criteria
Inclusion
- cancer patients undergoing anthracyclines based chemotherapy;
- heart rate (HR) \> 70 times per minute;
- Written informed consent.
Exclusion
- Contraindications for ivabradine administration;
- HR\<70 times per minute;
- Incapability to complete informed consent;
- Severe valve disease;
- Left ventricular ejection fraction (LVEF)≤ 30 %;
- Other severe conditions;
- Poor echogenicity.
Key Trial Info
Start Date :
June 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT04030546
Start Date
June 1 2019
End Date
December 31 2020
Last Update
December 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vilnius University Hospital Santaros klinikos
Vilnius, Lithuania, 08661